Most encouragingly, the company reports that nearly half (47%) of the study participants taking donanemab had no decline of cognition and function for one year (compared to 29% on placebo). The TRAILBLAZER-ALZ2 trial met all of its primary and secondary endpoints. The Centers for Medicare & Medicaid Services (CMS) policy to block Medicare access to Food and Drug Administration (FDA)-approved Alzheimer's treatments is in stark contrast to scientific evidence, is unprecedented and must be reversed immediately," said Joanne Pike, DrPH, Alzheimer's Association president and CEO. "These donanemab Phase 3 results are significant and further underscore the scientific evidence and personal benefit these types of treatments can have when people can get access to them. Full readout expected at Alzheimer's Association International Conference in JulyĬHICAGO, On behalf of the millions of Americans impacted by the devastation of Alzheimer's disease, the Alzheimer's Association enthusiastically welcomes the robustly positive topline data reported today by Eli Lilly on the TRAILBLAZER-ALZ2 Phase 3 clinical trial of donanemab for the treatment of early symptomatic Alzheimer's disease.Association underscores urgent call for CMS to stop blocking access to FDA-approved treatments.
Strongest Alzheimer's Phase 3 data release to date.
0 kommentar(er)
